budesonide/formoterol (Symbicort)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mild or Moderate Asthma
Conditions
Mild or Moderate Asthma
Trial Timeline
Oct 1, 2003 → Feb 1, 2005
NCT ID
NCT00646516About budesonide/formoterol (Symbicort)
budesonide/formoterol (Symbicort) is a phase 3 stage product being developed by AstraZeneca for Mild or Moderate Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00646516. Target conditions include Mild or Moderate Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00646516 | Phase 3 | Completed |
Competing Products
20 competing products in Mild or Moderate Asthma